
Government confirms increase to pharma’s statutory scheme
Despite opposition from the Association of the British Pharmaceutical Industry (ABPI), the UK government has confirmed its plans to raise the revenue clawback rate paid by pharma for branded medicines under the statutory scheme by just over 3%, from 24.4% to 27.5% for 2023.